<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.108265</article-id><article-id pub-id-type="publisher-id">ACM-37336</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200800000_29439329.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  比较安罗替尼联合同步放化疗与常规同步放化疗对局部晚期食管癌的疗效分析
  Comparison of the Efficacy of Anlotinib Combined with Concurrent Chemoradiotherapy (CCRT) and Conventional Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Esophageal Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>润泽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>世杰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>瑞霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>晓燕</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>逸涵</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>樊</surname><given-names>锐太</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>俊启</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>郑州大学第一附属医院内分泌科，河南 郑州</addr-line></aff><aff id="aff3"><addr-line>郑州大学医学院，河南 郑州</addr-line></aff><aff id="aff2"><addr-line>郑州大学第一附属医院放疗科，河南 郑州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2020</year></pub-date><volume>10</volume><issue>08</issue><fpage>1766</fpage><lpage>1772</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨安罗替尼联合同步放化疗对局部晚期食管癌的治疗效果及安全性分析。方法：选取2019-01-01到2020-04-30间我院收治的252例接受同步放化疗的局部晚期食管癌患者作为回顾性分析研究对象，其中21例加用盐酸安罗替尼药物联合同步放化疗方案，231例采用无盐酸安罗替尼的常规同步放化疗方案，利用倾向评分匹配(Propensity Score Matching, PSM)方法排除年龄、性别等非研究因素的干扰，最终入组42名病人(21名采用“安罗替尼 + 同步放化疗”方案，21名采用“常规同步放化疗”方案)，分别在治疗后第12周、24周、36周、48周、60周对患者进行疗效评价及不良反应评估，并跟踪统计两组患者食管癌的局部控制率。结果：安罗替尼联合同步放化疗方案组患者肿瘤局部控制率显著优于常规同步放化疗组患者(P &lt; 0.05)。安罗替尼组患者常见不良的反应为手足综合征(HFS)，安罗替尼组的患者手足综合征分级均为II级以下。常规同步放化疗方案组患者的主要不良反应为放射性食管炎及放射性肺炎。结论：安罗替尼联合同步放化疗较常规同步放化疗方案可明显提高食管癌局部晚期患者的肿瘤局部控制率，改善治疗效果。
    Objective: To investigate the efficacy and safety of anlotinib combined with CCRT in the treatment of locally advanced esophageal cancer. Methods: 252 patients with locally advanced esophageal cancer who received CCRT in our hospital from 2019-01-01 to 2020-04-30 were selected as subjects for retrospective analysis. Among them, 21 cases were treated with anlotinib hydrochloride combined with CCRT and chemotherapy, and 231 cases were treated with conventional concurrent chemoradiotherapy without anlotinib hydrochloride. The Propensity Score Matching (PSM) method was used to eliminate the interference of age, sex and other non-research factors. Finally, 42 patients were enrolled in the group (21 patients were treated with “anlotinib + CCRT” and 21 patients were treated with “conventional concurrent chemoradiotherapy”). The curative effect and adverse reactions were evaluated at 12 weeks, 24 weeks, 36 weeks, 48 weeks and 60 weeks after treatment, and the local control rate of esophageal cancer in the two groups was followed up. Conclusion: Compared with conventional concurrent chemoradiotherapy, anlotinib combined with CCRT can significantly improve the local control rate and therapeutic effect of patients with locally advanced esophageal cancer. 
  
 
</p></abstract><kwd-group><kwd>食管癌，安罗替尼，同步放化疗，局部控制率, Esophageal Carcinoma</kwd><kwd> Anlotinib</kwd><kwd> Concurrent Chemoradiotherapy (CCRT)</kwd><kwd> Local Control Rate</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>比较安罗替尼联合同步放化疗与常规同步放化疗对局部晚期食管癌的疗效分析</title><p>周润泽<sup>1</sup>，李世杰<sup>2</sup>，宋瑞霞<sup>1</sup>，王晓燕<sup>3</sup>，周逸涵<sup>1</sup>，樊锐太<sup>1</sup>，刘俊启<sup>1*</sup></p><p><sup>1</sup>郑州大学第一附属医院放疗科，河南 郑州</p><p><sup>2</sup>郑州大学医学院，河南 郑州</p><p><sup>3</sup>郑州大学第一附属医院内分泌科，河南 郑州</p><disp-formula id="hanspub.37336-formula75"><graphic xlink:href="//html.hanspub.org/file/36-1571481x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年8月3日；录用日期：2020年8月20日；发布日期：2020年8月27日</p><disp-formula id="hanspub.37336-formula76"><graphic xlink:href="//html.hanspub.org/file/36-1571481x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨安罗替尼联合同步放化疗对局部晚期食管癌的治疗效果及安全性分析。方法：选取2019-01-01到2020-04-30间我院收治的252例接受同步放化疗的局部晚期食管癌患者作为回顾性分析研究对象，其中21例加用盐酸安罗替尼药物联合同步放化疗方案，231例采用无盐酸安罗替尼的常规同步放化疗方案，利用倾向评分匹配(Propensity Score Matching, PSM)方法排除年龄、性别等非研究因素的干扰 [<xref ref-type="bibr" rid="hanspub.37336-ref1">1</xref>]，最终入组42名病人(21名采用“安罗替尼 + 同步放化疗”方案，21名采用“常规同步放化疗”方案)，分别在治疗后第12周、24周、36周、48周、60周对患者进行疗效评价及不良反应评估，并跟踪统计两组患者食管癌的局部控制率。结果：安罗替尼联合同步放化疗方案组患者肿瘤局部控制率显著优于常规同步放化疗组患者(P &lt; 0.05)。安罗替尼组患者常见不良的反应为手足综合征(HFS)，安罗替尼组的患者手足综合征分级均为II级以下。常规同步放化疗方案组患者的主要不良反应为放射性食管炎及放射性肺炎。结论：安罗替尼联合同步放化疗较常规同步放化疗方案可明显提高食管癌局部晚期患者的肿瘤局部控制率，改善治疗效果。</p><p>关键词 :食管癌，安罗替尼，同步放化疗，局部控制率</p><disp-formula id="hanspub.37336-formula77"><graphic xlink:href="//html.hanspub.org/file/36-1571481x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/36-1571481x8_hanspub.png" /> <img src="//html.hanspub.org/file/36-1571481x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>食管癌，是一种广泛发生于全球多个国家和地区，具有恶性程度高、死亡率高、复发率高、治疗效果差、放化疗不敏感、五年生存率低等临床特点的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.37336-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37336-ref3">3</xref>]。中国是食管癌的高发国家之一，平均每年约有15万人死于食管癌，中国的食管癌患者中，90%以上食管癌的临床病理类型为鳞状细胞癌。由于食管癌隐匿性高，早期临床症状不易察觉，大多数食管癌发现时已处于局部晚期，丧失手术切除的条件 [<xref ref-type="bibr" rid="hanspub.37336-ref4">4</xref>]。目前，临床上对于局部晚期的食管癌患者(主要为食管发生癌变，侵及食管及周围组织，但没有重要脏器与远处转移的患者)的治疗方案主要是同步放化疗 [<xref ref-type="bibr" rid="hanspub.37336-ref5">5</xref>]。其中，化疗方案主要为以5-FU、顺铂和紫杉醇为主的联合化疗方案进行治疗，放疗方案目前我院采用常规剂量适形调强放疗联合化疗，放疗剂量为54~60.0 Gy，每次1.8 Gy或2.0 Gy (颈段食管癌患者每次2.0 Gy，总剂量为60 Gy)。盐酸安罗替尼是一种新型的小分子多靶点酪氨酸激酶抑制剂，可有效抑制血管内皮细胞生长因子受体(VEGFR)、血小板衍生生长因子受体(PDGFR)、成纤维细胞生长因子受体(FGFR)和c-Kit等激酶，具有显著抗肿瘤血管生成和抑制肿瘤生长的作用 [<xref ref-type="bibr" rid="hanspub.37336-ref6">6</xref>]。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>本研究选取自2019-01-01至2020-04-30之间接受治疗的局部晚期食管癌患者共252例(其中21例采用安罗替尼联合放射治疗方案，231例采用常规同步放化疗方案)，利用倾向评分匹配(PSM)方法匹配以排除年龄、性别、基础疾病等非研究混杂因素的干扰，最终入组21例安罗替尼联合同步放化疗的患者，21例采用常规同步放化疗方案的患者。该研究项目的内容及过程遵循国际及国家颁布的有关生物医学研究的伦理要求，并已获得郑州大学第一附属医院伦理审查委员会的伦理许可。患者纳入标准为：① 符合《食管和食管胃结合部癌规范化诊治指南》中食管癌的相关诊断标准 [<xref ref-type="bibr" rid="hanspub.37336-ref7">7</xref>]；② 患者均经紫杉醇类、铂类和氟尿嘧啶类药物两药或三药联合治疗失败，目前为三线治疗；③ 卡氏功能状态(Karnofsky performance status, KPS)评分 ≥ 60分，预计生存期 &gt; 3个月；④ 均有可测量的病灶，病灶长度不超过10 cm；⑤ TNM分期为II/III期的局部晚期食管癌患者；⑥ 符合安罗替尼靶向治疗的临床指征。排除标准：① 食管癌TNM分期为III期但T分期为T4的患者(有出血倾向)；② 存在食管或胃肠道溃疡；③ 肝、肾功能不全，特别是尿蛋白定量 &gt; 3.0 g/24h；④ 血小板计数 &lt; 75 &#215; 10<sup>9</sup>。安罗替尼联合同步放化疗组共21人，其中男14人，女7人。常规同步放化疗方案组共21人，其中男13人，女8人。</p></sec><sec id="s4_2"><title>2.2. 治疗方案</title><sec id="s4_2_1"><title>2.2.1. 安罗替尼联合同步放化疗组</title><p>放射治疗，给予直线加速器高能X线三维适形放射治疗，5次/周，1.8~2.0 Gy/次，总剂量为54~60 Gy (GTV 60 Gy；CTV 54 Gy；颈段食管癌患者2.0 Gy每次，总剂量为60 Gy)，连续治疗6周。同时给予化疗方案(顺铂 + 氟尿嘧啶)，顺铂剂量为25 mg/m<sup>2</sup> d1-3；氟尿嘧啶剂量为1800 mg/m<sup>2</sup>d1q4w*2 (四周方案)。治疗室每隔2周对患者进行一次钡餐摄片检查，以明确患者有无穿孔情况。盐酸安罗替尼的给药方式为12 mg，1次用两周停一周，21天为一周期。</p></sec><sec id="s4_2_2"><title>2.2.2. 常规同步放化疗方案组</title><p>常规同步放化疗组与安罗替尼联合放疗组的放疗方案一致，直线加速器高能X线三维适形放射治疗，5次/周，1.8~2.0 Gy/次，总剂量为54~60 Gy (GTV 60 Gy；CTV 54 Gy；颈段食管癌患者2.0 Gy每次，总剂量为60 Gy)，连续治疗6周。同时给予化疗方案(顺铂 + 氟尿嘧啶)，顺铂剂量为25 mg/m<sup>2</sup> d1-3；氟尿嘧啶剂量为1800 mg/m<sup>2</sup> d1q4w*2 (四周方案)。治疗室每隔2周对患者进行一次钡餐摄片检查，以明确患者有无穿孔情况。无盐酸安罗替尼用药。</p></sec></sec><sec id="s4_3"><title>2.3. 疗效评价及不良反应</title><p>通过计算患者各阶段局部控制率和来评价其总体疗效。局部控制定义为食管X线片提示食管癌消失，黏膜无破坏或治疗结束肿瘤有残留，随诊过程中稳定或有缩小并维持2个月以上。毒副反应评价标准：放疗急性反应和晚期反应评价采用1995年RTOG标准 [<xref ref-type="bibr" rid="hanspub.37336-ref8">8</xref>]；化疗采用NCI普通毒性标准-CTC2.0 [<xref ref-type="bibr" rid="hanspub.37336-ref9">9</xref>]。</p></sec><sec id="s4_4"><title>2.4. 统计学方法</title><p>数据采用SPSS 21.0统计软件进行分析，比率的比较采用卡方检验，生存情况分别用接受治疗后的第12周、24周、36周、48周、60周的局部控制率情况进行评估，以P &lt; 0.05为差异具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 两组患者的一般情况比较</title><p>两组患者(安罗替尼联合同步放化疗组与常规同步放化疗方案)在年龄、性别、病变部位、病变直径、ECOG评分、分化程度及TNM分期方面经倾向评分匹配(PSM)后均无统计学差异(P &gt; 0.05，见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical characteristics between two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle"  colspan="2"  >安罗替尼同步放化疗</th><th align="center" valign="middle"  colspan="2"  >常规同步放化疗方案</th><th align="center" valign="middle" >c<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >(66.67%)</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >(61.90%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.872</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >(38.10%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中位年龄</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >65</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;50</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >(23.81%)</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.881</td></tr><tr><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >(76.19%)</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >(66.67%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病变部位</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >颈段</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >(14.29%)</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >(14.29%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.765</td></tr><tr><td align="center" valign="middle" >胸上段</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >(23.81%)</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >胸中段</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >(42.86%)</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >胸下段</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >(19.05%)</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >(23.81%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病变长度(cm)</td><td align="center" valign="middle" >5.7 &#177; 1.3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5.4 &#177; 1.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >——</td><td align="center" valign="middle" >0.821</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >(19.05%)</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.698</td></tr><tr><td align="center" valign="middle" >中</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >(47.62%)</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >(42.86%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >低</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TNM分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >II期</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >(42.86%)</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >(47.62%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.631</td></tr><tr><td align="center" valign="middle" >III期(除T4)</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >(57.14%)</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >(52.38%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ECOG评分</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.664</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >(52.38%)</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >(47.62%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >(19.05%)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >(19.05%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 两组患者的一般特征比较</p></sec><sec id="s5_2"><title>3.2. 两组患者治疗的局部控制率比较</title><p>根据两组患者12周、24周、36周、48周、60周的局部控制率比较，安罗替尼联合同步放化疗组的局部控制率为63.9%、69.4%、72.2%、80.1%、82.8%，显著高于常规同步放化疗方案组(P &lt; 0.05，见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of local control rate between the two groups during the observation perio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >安罗替尼同步放化疗</th><th align="center" valign="middle" >常规同步放化疗方案</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >12周</td><td align="center" valign="middle" >63.9%</td><td align="center" valign="middle" >44.7%</td><td align="center" valign="middle" >0.0171</td></tr><tr><td align="center" valign="middle" >24周</td><td align="center" valign="middle" >69.4%</td><td align="center" valign="middle" >46.1%</td><td align="center" valign="middle" >0.0085</td></tr><tr><td align="center" valign="middle" >36周</td><td align="center" valign="middle" >72.2%</td><td align="center" valign="middle" >49.2%</td><td align="center" valign="middle" >0.0105</td></tr><tr><td align="center" valign="middle" >48周</td><td align="center" valign="middle" >80.1%</td><td align="center" valign="middle" >52.3%</td><td align="center" valign="middle" >0.0063</td></tr><tr><td align="center" valign="middle" >60周</td><td align="center" valign="middle" >82.8%</td><td align="center" valign="middle" >56.5%</td><td align="center" valign="middle" >0.0056</td></tr></tbody></table></table-wrap><p>表2. 两组患者各观察期内的局部控制率比较</p></sec><sec id="s5_3"><title>3.3. 两组患者毒副反应发生情况比较</title><p>安罗替尼联合同步放化疗组的患者主要出现的不良反应为手足综合征(HFS)，患者出现的手足综合征分级均为II级以下(I级患者可自行恢复，II级患者经皮肤科对症处理后可恢复)。常规同步放化疗方案组患者出现的不良反应主要为放射性食管炎与放射性肺炎。放射性食管炎及放射性肺炎经支持治疗及对症处理后均可恢复。两组患者除手足综合征外其余非特异性不良反应发生情况均无统计学差异(P &gt; 0.05，见表3)。患者手足皮肤反应的分级按照手足皮肤反应分级标准(NCI-CTC AE 4.0)评价(见表4)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of toxic and side effects between the two groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle"  colspan="2"  >安罗替尼同步放化疗</th><th align="center" valign="middle"  colspan="2"  >常规同步放化疗方案</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >手足皮肤反应</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I级</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" >——</td><td align="center" valign="middle" >——</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >II级</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >(9.52%)</td><td align="center" valign="middle" >——</td><td align="center" valign="middle" >——</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血压升高</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >(9.52%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >(4.76%)</td><td align="center" valign="middle" >0.822</td></tr><tr><td align="center" valign="middle" >放射性皮炎</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >(19.05%)</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" >0.779</td></tr><tr><td align="center" valign="middle" >放射性气管炎</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" >0.814</td></tr><tr><td align="center" valign="middle" >放射性食管炎</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >(19.05%)</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" >0.612</td></tr><tr><td align="center" valign="middle" >白细胞减少</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >(28.57%)</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >(33.33%)</td><td align="center" valign="middle" >0.797</td></tr><tr><td align="center" valign="middle" >中性粒细胞减少</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >(9.52%)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >(19.05%)</td><td align="center" valign="middle" >0.721</td></tr><tr><td align="center" valign="middle" >血红蛋白减少</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >(14.29%)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >(4.76%)</td><td align="center" valign="middle" >0.798</td></tr></tbody></table></table-wrap><p>表3. 两组患者的毒副反应发生情况比较</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Hand and foot skin reaction grading standard (NCI-CTC AE 4.0</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分级</th><th align="center" valign="middle" >定义</th></tr></thead><tr><td align="center" valign="middle" >I级</td><td align="center" valign="middle" >轻微皮肤改变或皮肤炎(局部红肿、水肿、角化过度、无痛)，但不影响日常生活</td></tr><tr><td align="center" valign="middle" >II级</td><td align="center" valign="middle" >皮肤改变明显(剥落、水泡、出血、肿胀、角化过度)，疼痛，影响日常生活和活动</td></tr><tr><td align="center" valign="middle" >III级</td><td align="center" valign="middle" >重度皮肤改变(剥落、水泡、溃疡、出血、水肿、角化过度)，疼痛明显，个人自理能力受限</td></tr></tbody></table></table-wrap><p>表4. 手足皮肤反应分级标准(NCI-CTC AE 4.0)</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>根据最新版食管癌临床规范化治疗指南，目前食管癌的治疗依旧首选手术治疗，术式可根据患者病情、意愿等情况选择开放食管癌切除术或微创食管癌切除术 [<xref ref-type="bibr" rid="hanspub.37336-ref10">10</xref>]。但食管癌起病较隐匿，临床症状出现周期较晚，常常一经诊断即进入食管癌局部晚期，甚至出现远处转移，丧失手术治疗的机会，5年生存率不足20.0%，且术后复发率与转移率一直维持高位，为此需要同步放化疗已改善患者预后 [<xref ref-type="bibr" rid="hanspub.37336-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.37336-ref11">11</xref>]。目前针对局部晚期食管癌，指南仍然推荐首选同步放化疗方案，可有效提高食管癌患者治疗的局部控制率并改善远期生存状态 [<xref ref-type="bibr" rid="hanspub.37336-ref12">12</xref>]。RTOG 8501研究显示同步放化疗可以显著提高肿瘤局部控制率，增加远期生存率，5年生存率优于单纯放疗 [<xref ref-type="bibr" rid="hanspub.37336-ref13">13</xref>]。RTOG 8501研究后，同步放化疗逐渐成为食管癌非手术治疗的标准方案，并已被美国NCCN推荐列为治疗不可切除的局部晚期食管鳞状细胞癌患者的标准方案。</p><p>肿瘤的发生、发展、扩散和转移都需要充足的营养供应，与丰富的血管与淋巴管道密切相关。研究证明血管内皮生长因子(VEGF)是一种强效诱导血管生成的蛋白质，在生理及病理条件下均可直接作用于血管内皮细胞从而影响肿瘤的增殖、转移和血管形成 [<xref ref-type="bibr" rid="hanspub.37336-ref14">14</xref>]。同时，有研究表明VEGF高表达与包括食管癌在内的多种肿瘤的预后情况差密切相关 [<xref ref-type="bibr" rid="hanspub.37336-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.37336-ref16">16</xref>]。食管癌组织中常常检测出高表达的VEGF。目前针对VEGF靶向治疗药物的临床应用研究较少。盐酸安罗替尼是我国自主研发的新型小分子多靶点酪氨酸激酶抑制剂，可强效针对性抑制VEGFR、PDGFR、FGFR等多个靶点，具有抑制肿瘤血管生成和肿瘤生长的作用。同时安罗替尼为口服型药物，使用方便，不良反应较轻，患者依从性较好，可提高患者的生存质量。</p></sec><sec id="s7"><title>5. 结论</title><p>本实验旨在验证安罗替尼应用于临床诊断食管癌局部晚期病例的治疗效果，取得了显著疗效。本实验共入组42名患者，其中联合安罗替尼同步放化疗组共21人，至观察期结束(60周)总体局部控制率为82.8%，显著高于常规同步放化疗方案组，应用联合安罗替尼同步放化疗的患者局部控制率及观察期内生存率均显著高于常规同步放化疗方案组。联合安罗替尼同步放化疗组的患者不良反应与常规同步放化疗方案组患者发生情况的组间差别无统计学意义。</p><p>综上研究结果表明联合安罗替尼同步放化疗方案较常规同步放化疗方案可更有效地治疗局部晚期食管癌，提高患者的生存质量，值得临床广泛应用。远期的生存状况及对患者带瘤生存状况的影响有待更大规模、更长周期的回顾性或前瞻性临床探索。</p></sec><sec id="s8"><title>基金项目</title><p>河南省高等学校重点科研项目(19A320036)；河南省医学科技攻关计划联合共建项目(2018020011)。</p></sec><sec id="s9"><title>文章引用</title><p>周润泽,李世杰,宋瑞霞,王晓燕,周逸涵,樊锐太,刘俊启. 比较安罗替尼联合同步放化疗与常规同步放化疗对局部晚期食管癌的疗效分析Comparison of the Efficacy of Anlotinib Combined with Concurrent Chemoradiotherapy (CCRT) and Conventional Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Esophageal Cancer[J]. 临床医学进展, 2020, 10(08): 1766-1772. https://doi.org/10.12677/ACM.2020.108265</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37336-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Abrahami, D., Pradhan, R., Yin, H., et al. (2020) Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision-Making: Assessing the Impact of Temporality, comparator choice and Methods of Adjustment. Clinical Pharmacology and Therapeutics. &lt;br&gt;https://doi.org/10.1002/cpt.2012</mixed-citation></ref><ref id="hanspub.37336-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">赵维勇, 张丽珍, 王继荣. 三维适形放疗联合不同化疗方案治疗中晚期食管癌的临床研究[J]. 现代肿瘤医学, 2012, 20(5): 956-958. &lt;br&gt;https://doi.org/10.3969/j.issn.1672-4992.2012.05.25</mixed-citation></ref><ref id="hanspub.37336-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">乔友林. 食管癌流行病学研究的重要里程碑[J]. 中国肿瘤临床, 2016, 43(12): 500-501.  
&lt;br&gt;https://doi.org/10.3969/j.issn.1000-8179.2016.12.551</mixed-citation></ref><ref id="hanspub.37336-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">关春莹. 多烯紫杉醇联合奈达铂同步放化疗治疗局部中晚期食管癌疗效分析[J]. 健康大视野, 2019(14): 51-52.  
&lt;br&gt;https://doi.org/10.3969/j.issn.1005-0019.2019.14.081</mixed-citation></ref><ref id="hanspub.37336-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">李杨, 陈贡斌, 闫艳菊. 奈达铂+替吉奥化疗方案联合3D-CRT治疗局部晚期食管癌临床研究[J]. 肿瘤学杂志, 2018, 24(2): 125-128.</mixed-citation></ref><ref id="hanspub.37336-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">翟医蕊. 食管鳞癌的放射治疗联合靶向治疗及放化疗疗效预测指标的研究术中放疗在腹部肿瘤中的应用[D]: [博士学位论文]. 北京: 清华大学医学部, 北京协和医学院, 中国医学科学院, 2012.</mixed-citation></ref><ref id="hanspub.37336-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ajani, J., D’Amico, T., Bentrem, D., et al. (2019) Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 855-883. &lt;br&gt;https://doi.org/10.6004/jnccn.2019.0033</mixed-citation></ref><ref id="hanspub.37336-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kachnic, L., Winter, K., Wasserman, T., et al. (2011) Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123): A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointestinal Cancer Research, 4, 45-52.</mixed-citation></ref><ref id="hanspub.37336-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Tucker, S., Jin, H., Wei, X., et al. (2010) Impact of Toxicity Grade and Scoring System on the Relationship between Mean Lung Dose and Risk of Radiation Pneumonitis in a Large Cohort of Patients with Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 77, 691-698. 
&lt;br&gt;https://doi.org/10.1016/j.ijrobp.2009.05.055</mixed-citation></ref><ref id="hanspub.37336-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">秦海峰, 游继军, 丁海兵, 等. 微创食管癌切除术和开放食管癌切除术治疗食管鳞状细胞癌的淋巴结清扫效果及并发症比较[J]. 癌症进展, 2020, 18(10): 1057-1060.</mixed-citation></ref><ref id="hanspub.37336-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">李丹丹, 亢崇照, 赵芳宗, 等. 同期放化疗模式下不同放疗剂量对局部晚期食管癌患者的疗效及安全性[J]. 癌症进展, 2020, 18(8): 799-802+830.</mixed-citation></ref><ref id="hanspub.37336-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王永锋. 同步放化疗治疗中晚期食管癌疗效分析[J]. 中外女性健康研究, 2020, 7(30): 36.</mixed-citation></ref><ref id="hanspub.37336-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, K.L., Ma, J.B., Liu, G., Wu, K.-L., Shi, X.H. and Jiang, G.L. (2010) Three-Dimensional Conformal Radiation Therapy for Esophageal Squamous Cell Carcinoma: Is Elective Nodal Irradiation Necessary? International Journal of Radiation Oncology, Biology, Physics, 76, 446-451. &lt;br&gt;https://doi.org/10.1016/j.ijrobp.2009.02.078</mixed-citation></ref><ref id="hanspub.37336-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Du, J.-R., Jiang, Y., Zhang, Y.-M. and Hong, F. (2003) Vascular Endothelial Growth Factor and Microvascular Density in Esophageal and Gastric Carcinomas. World Journal of Gastroenterology, 9, 1604-1606. 
&lt;br&gt;https://doi.org/10.3748/wjg.v9.i7.1604</mixed-citation></ref><ref id="hanspub.37336-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Juchniewicz, A., Niklińska, W., Kowalczuk, O., Wojciech, L., et al. (2015) Prognostic Value of Vascular Endothelial Growth Factor-C and Podoplanin mRNA Expression in Esophageal Cancer. Oncology Letters, 10, 3668-3674. 
&lt;br&gt;https://doi.org/10.3892/ol.2015.3824</mixed-citation></ref><ref id="hanspub.37336-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Choi, J.Y., Jang, K.T., Shim, Y.M., et al. (2006) Prognostic Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Esophageal Squamous Cell Carcinoma: Comparison with Positron Emission Tomography. Annals of Surgical Oncology, 13, 1054-1062. &lt;br&gt;https://doi.org/10.1245/ASO.2006.08.012</mixed-citation></ref></ref-list></back></article>